Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

M.D. Anderson Cancer Center (Other)
Overall Status
Active, not recruiting ID
Anticipated Duration (Months)
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.

Condition or DiseaseIntervention/TreatmentPhase
  • Other: Fitbit
  • Other: Continuous Glucose Monitor

Detailed Description

Primary objective:

To evaluate the feasibility of a CGM-based physical activity intervention that includes the use of CGM and FitbitĀ®.

Secondary objectives:

To examine changes in physical activity motivation and other related psychosocial variables (e.g., intention, perceived benefits, outcome expectancy) before and after the intervention.

Exploratory objective:

Examine cancer-related biomarkers and their associations with daily glucose pattern.

Study Design

Study Type:
Actual Enrollment :
35 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices
Actual Study Start Date :
May 24, 2018
Anticipated Primary Completion Date :
Jan 31, 2022
Anticipated Study Completion Date :
Jan 31, 2022

Arms and Interventions

Experimental: Heart Rate Tracker (Fitbit)

continuous heart rate activity

Other: Fitbit
wearable activity tracker

Other: Continuous Glucose Monitor
wearable activity tracker

Experimental: Continuous Glucose Monitor (CGM)

monitoring daily exercise-related activities

Other: Fitbit
wearable activity tracker

Other: Continuous Glucose Monitor
wearable activity tracker

Outcome Measures

Primary Outcome Measures

  1. To evaluate the feasibility of the ( PA) Physical Activity intervention. [through study completion, an average of 1 year]

    The use of CGM through the following criteria: CGM-specific refusal rate <20% at the participant recruitment phase and protocol adherence rates >80% at the end of the monitoring period.

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Men and women at least 18 years old

  • Body mass index (BMI) 25 kg/m2

  • Engage in less than 150 minutes of moderate-intensity PA per week in the past month

  • Capable of participating in moderate-vigorous unsupervised exercise (as determined by the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their physician)

  • Self-reported ability to walk one block without pain or discomfort

  • Have a smart phone with daily internet access that is compatible with the LibreLink app

  • Ability to speak, read, and write in English

  • For the cancer survivor cohort (participant accession number #21 and beyond), individuals must have been diagnosed with stage I-III breast or colorectal cancer and completed adjuvant therapy (i.e., chemo and/or radiation therapy).

Exclusion Criteria:
  • Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes

  • Self-reported use of oral antidiabetic agents (OADs)

  • Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator)

  • Current use of a continuous glucose monitor

  • Fasting glucose > 125 mg/dL

  • Pregnancy

  • Self-reported health issues that limit physical activity

  • On dialysis

  • Work overnight shifts

  • Unwilling to use CGM

  • Current participation in other wellness or weight loss-related program or intervention

  • Currently on a low-carb diet

  • Unable to receive REDCap survey through their mobile phones

Contacts and Locations


SiteCityStateCountryPostal Code
1M D Anderson Cancer CenterHoustonTexasUnited States77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center


  • Principal Investigator: Karen Basen-Engquist, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:


None provided.
Responsible Party:
M.D. Anderson Cancer Center Identifier:
Other Study ID Numbers:
  • 2018-0299
First Posted:
Nov 18, 2021
Last Update Posted:
Nov 26, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:

Study Results

No Results Posted as of Nov 26, 2021